Navigation Links
ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas
Date:3/31/2011

SAN CLEMENTE, Calif., March 31, 2011 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (Nasdaq: ICUI) today announced that it will initiate the full market release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. MicroCLAVE Clear allows clinicians to visualize the fluid path, verifying effective flushing of the patient catheter after use with blood and medications that could leave residual or fluid precipitates after aspiration or infusion. The connector's clinically proven MicroCLAVE design effectively clears blood and blood residual with flush volumes as low as 2.0 mL, while the connector's clear housing allows for visualization of the internal fluid path upon flushing the connector.

In a recent study comparing the flushing efficiency of different designs of clear needlefree connectors, the neutral displacement MicroCLAVE Clear was shown to be superior to either the positive displacement CareFusion® MaxPlus® or the negative displacement Baxter® ClearLink® as determined by the total flush volume needed to clear the connector of blood elements. The study showed that the MicroCLAVE Clear was free of blood residual after an average of 2.5mL saline flush, with 60% of the connectors flushing clear with only a 2 mL flush. By contrast, 100% of the MaxPlus connectors tested showed residual blood after a 10mL saline flush, as did 40% of the ClearLink connectors.(1)

Previous studies have demonstrated that the more proteinaceous material—including small blood clots—that resides in the connector hub, the greater the chance infection.(2) Infection is a major concern in the hospital environment and especially so given the issues of antibiotic resistance and hospital acquired infection.

Part of a full line of MicroCLAVE connectors that includes the original MicroCLAVE and the antimicrobial MicroCLAVE, MicroCLAVE Clear shares the design features that have been clinically proven to provide a safe and effective microbial barrier. The neutral displacement straight fluid path design, split-septum, and minimal deadspace of the MicroCLAVE work together to help minimize blood reflux into the tip of the catheter upon connection or disconnection of the luer. Not only does the MicroCLAVE provide enhanced patient safety through innovative technology but it has also been proven to provide an effective microbial barrier against bacteria transfer and contamination.(3-5) In addition, The MicroCLAVE's neutral displacement design may help hospitals address recent concerns raised by the FDA regarding the safety of positive displacement connectors.(6)

Media Contact: Tom McCall
Vice President, Marketing
949-366-4368
tmccall@icumed.com

(1) Sylvia, C. DVM, MS, Breznock E. DVM, PhD, Diplomate ACVS. The in vivo evaluation of the flushing efficiency of different designs of clear needlefree connectors, data on file at ICU Medical, February 2011. (2) Jarvis WR, et al Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device. Infect Control Hosp Epidemiol. 1998 Jan; 19(1):23-7 (3) ECRI Institute, Health Devices. Evaluation of Needleless Connectors. September 2008, Volume 37, Number 9: 259-286. (4) Ryder M, RN, PhD. Bacterial transfer through needlefree connectors: Comparison of nine different devices. Poster presented at the Annual Society for Healthcare Epidemiology of America (SHEA) conference 2007, Abstract 412. (5) Moore C, RN, MBA, CIC. Maintained Low Rate of Catheter-Related Bloodstream Infections (CR-BSIs) After Discontinuation of a Luer Access Device (LAD) At an Academic Medical Center. Poster presented at the annual Association for Professionals in Infection Control and Epidemiology (APIC) Conference 2010, Abstract 4-028. (6) FDA Medical Device Safety Alert, July 28, 2010: Letter to Infection Control Practitioners Regarding Positive Displacement Needleless Connectors (http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm220459.htm).


'/>"/>
SOURCE ICU Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):